BCR and cancer: Imatinib is a tyrosine kinase specific inhibitor specifically designed to fit the BCR-Abl ATP-binding site of the protein created by the BCR-Abl translocation enabling for the first time specific cancer therapy by targeting a causal molecular target [7].